Vaginal progesterone for luteal support in early pregnancy
Vaginal micronized progesterone is recommended only for threatened miscarriage when vaginal bleeding is present in a current intrauterine pregnancy and there is a history of miscarriage.[1] Serum progesterone level and hCG rise do not define an indication for luteal-support progesterone.[1]
Indication criteria for progesterone use
Vaginal micronized progesterone 400 mg twice daily should be offered when all the following are met:[1]
- Confirmed intrauterine pregnancy by scan with fetal heartbeat.[1]
- Vaginal bleeding in the current pregnancy.[1]
- Prior miscarriage history.[1]
Medication selection algorithm
- Vaginal micronized progesterone (400 mg twice daily) is the progesterone regimen specified for threatened miscarriage in this setting.[1]
- No progesterone regimen is recommended by this guideline for use solely on the basis of luteal-support laboratory values (eg, progesterone level) or hCG doubling pattern without vaginal bleeding.[1]
Treatment initiation and duration
- Progesterone should be started when a confirmed intrauterine pregnancy is established by scan.[1]
- Progesterone should be continued until 16 completed weeks of pregnancy when a fetal heartbeat is confirmed.[1]
Monotherapy versus combination therapy
- Progesterone therapy in this guideline recommendation is a progesterone monotherapy approach.[1]
- No additional luteal-support agents are recommended as part of this progesterone strategy.[1]
Key evidence supporting this recommendation
- The NICE recommendation states that evidence supports increased live births with 400 mg twice daily micronized vaginal progesterone in women with early pregnancy bleeding and a previous miscarriage.[1]
- NICE also states that there is no evidence of benefit for progesterone in other scenarios including previous miscarriage without early pregnancy bleeding in the current pregnancy.[1]
Important clarifications for the presented scenario
A 5 weeks + 3 days pregnancy with normal hCG doubling and serum progesterone of 13 ng/mL does not, by itself, meet the NICE eligibility criteria because eligibility requires vaginal bleeding in the current pregnancy plus scan-confirmed intrauterine pregnancy in a patient with a history of miscarriage.[1]
Target outcome of therapy
- Therapy is intended to improve live-birth outcomes in the subset of threatened miscarriage with vaginal bleeding and prior miscarriage history.[1]